| Name | Title | Contact Details |
|---|
Brightseed enables a healthier future by illuminating and activating the connections between people and plants. Despite centuries of wisdom proving the critical roles plants play in supporting our health, the majority of active compounds in the plant kingdom remain unexplored. Our artificial intelligence, Forager®, reveals powerful compounds hidden in nature and our team scientifically validates their impact.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
GrowBLOX Sciences (OTCQ GBLX) – merges state-of-the-art technologies in plant biology, cultivation and post-production processes in order to optimize safe, consistent medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients in communities across the country.
Morgan Advanced Ceramics is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stellar Biotechnologies is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimers, and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.